Takeda Pharmaceutical Co Ltd (FRA:TKDA) Stock News, Headlines & Updates
Takeda Pharmaceutical Co Ltd Stock News from GuruFocus
- 1
- 2
Jul 21, 2025
TAK's TAK-861 Faces Competition Amid Narcolepsy Treatment Study Results | TAK Stock News
GuruFocus News • 10:16am
Takeda Pharmaceutical Co Ltd (TAK) Announces FDA Clearance for HyHub and HyHub Duo Devices | TAK stock news
GuruFocus News • 8:12am
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
Business Wire • 8:00am
FDA Clears Takeda's (TAK) Innovative Devices for Needle-Free Infusion | TAK Stock News
GuruFocus News • 7:21am
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration | TAK Stock News
GuruFocus News • 7:20am
Jul 17, 2025
Milestone Payment of $10 Million Triggered for Takeda (TAK) in Elritercept Trial | TAK Stock News
GuruFocus News • 7:30am
Jul 14, 2025
TAK: Takeda's Narcolepsy Drug Shows Promise in Phase 3 Trials
GuruFocus News • 8:56am
Takeda (TAK) Achieves Positive Results in Phase 3 Trials for Oveporexton | TAK Stock News
GuruFocus News • 4:45am
Takeda Pharmaceutical Co Ltd (TAK) Announces Successful Phase 3 Trials for Oveporexton in Narcolepsy Type 1 | TAK stock news
GuruFocus News • 4:02am
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Business Wire • 3:00am
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 | TAK Stock News
GuruFocus News • 2:15am
Jul 10, 2025
Improving Margins, Cash Flow Strength, and an Undervalued Opportunity
Saba Sadiq • 2:21pm
Jun 30, 2025
FDA Approves Takeda's GAMMAGARD LIQUID ERC for Primary Immunodeficiency | TAK stock news
GuruFocus News • 8:10am
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Business Wire • 8:00am
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ | TAK Stock News
GuruFocus News • 7:22am
Jun 25, 2025
Takeda Pharmaceutical Co Ltd (TAK) Announces New Director Assignments | TAK stock news
GuruFocus News • 3:01am
Takeda Announces New Assignments of Directors
Business Wire • 3:00am
Takeda Announces New Assignments of Directors | TAK Stock News
GuruFocus News • 2:15am
Jun 03, 2025
European Commission Approves Takeda (TAK) and Pfizer Drug Adcetris for Hodgkin Lymphoma
GuruFocus News • 11:55am
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Business Wire • 10:00am
Takeda (TAK) Gains EU Approval for Adcetris in Hodgkin Lymphoma Treatment | TAK Stock News
GuruFocus News • 9:30am
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD | TAK Stock News
GuruFocus News • 9:30am
Jun 01, 2025
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
GuruFocus News • 7:15am
May 27, 2025
Takeda Pharmaceutical Co Ltd (TAK) Opens Applications for Innovators in Science Award | TAK stock news
GuruFocus News • 8:06am
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Business Wire • 7:00am
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award | TAK Stock News
GuruFocus News • 6:48am
May 14, 2025
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Business Wire • 5:00pm
Takeda (TAK) Reports Promising Phase 2b Trial Results for Narcolepsy Treatment | TAK Stock News
GuruFocus News • 4:30pm
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 | TAK Stock News
GuruFocus News • 4:16pm
May 09, 2025
Full Year 2025 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
GuruFocus News • 8:13am
May 08, 2025
Takeda Pharmaceutical Co Ltd (TAK) Stock Price Down 4.42% on May 8
GuruFocus News • 12:10pm
Takeda Pharmaceutical (TAK) Announces FY2024 Financial Results and FY2025 Outlook
GuruFocus News • 2:55am
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
Business Wire • 2:00am
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress | TAK Stock News
GuruFocus News • 1:45am
May 07, 2025
What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings
GuruFocus News • 7:15am
May 05, 2025
Takeda Pharmaceutical Co Ltd (TAK) Introduces Innovative Plasma Collection Technology | TAK stock news
GuruFocus News • 8:08am
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
Business Wire • 8:00am
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers | TAK Stock News
GuruFocus News • 7:24am
Apr 30, 2025
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news